PLOS ONE

Vegan Cats Challenge Carnivorous Expectations

Retrieved on: 
Friday, September 15, 2023
PLOS, Nutrient, WINCHESTER, Health, PLOS ONE, Risk, Cat, Animal feed

Whilst biologically carnivorous, cats are increasingly being fed vegan diets - and thriving!

Key Points: 
  • Whilst biologically carnivorous, cats are increasingly being fed vegan diets - and thriving!
  • In fact, a ground-breaking new study has just found that cats are healthier, when fed vegan diets.
  • It studied 1,369 cats fed vegan or meat-based pet food, for at least one year.
  • Forty two percent of cats fed meat suffered from at least one health disorder, whereas this fell to 37% amongst vegan cats.

bioAffinity Technologies Publishes Peer-Reviewed Results of High-Throughput Flow Cytometry Use for Evaluating Lung Health in PLOS ONE

Retrieved on: 
Wednesday, September 14, 2022
Biotechnology, FDA, Health, Other Health, Radiology, Pharmaceutical, Surgery, Oncology, Other Science, Research, Medical Devices, Genetics, Science, Clinical Trials, PLOS, University of Texas Health Science Center at San Antonio, Health, Laboratory, Time, Phlegm, LLC, Research, LDT, Flow cytometry, Company, BIAF, Sputum, University, Forward-looking statement, Lung cancer, Survival, Lung, Cancer, Laboratory developed test, PLOS ONE, Technology, Cell, Diagnosis, NASDAQ, Biotechnology, COPD, Disease, Medical imaging

The journal PLOS ONE , published Sputum analysis by flow cytometry; an effective platform to analyze the lung environment reporting on results of analyzing sputum by flow cytometry as the basis for high-throughput diagnostic tests to determine the health of the lung.

Key Points: 
  • The journal PLOS ONE , published Sputum analysis by flow cytometry; an effective platform to analyze the lung environment reporting on results of analyzing sputum by flow cytometry as the basis for high-throughput diagnostic tests to determine the health of the lung.
  • The PLOS ONE paper presents our unique method for determining the health of an individuals lungs, bioAffinity President and CEO Maria Zannes said.
  • Flow cytometry allows for analysis of whole cells and cell populations that make up the lung environment.
  • bioAffinity Technologies is addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment.

Replica Analytics' new estimator uses synthetic data for more reliable evaluation of re-identification risk in datasets

Retrieved on: 
Tuesday, July 19, 2022
PLOS, Aetion, SDG, Safety, RWD, PLOS ONE, Technology, Synthetic, Replica, General manager, RWE, Probability, Privacy, Organization, Industry, Risk, Senior, Epidemiology, Data, Health, Population, Medical device, Risk management

The re-identification risk estimator we have developed should help data custodians overcome those challenges."

Key Points: 
  • The re-identification risk estimator we have developed should help data custodians overcome those challenges."
  • Most existing estimators provide a proxy for risk based on strong assumptions, as they cannot calculate the risk on a population because real population data is rarely available.
  • Synthetic data generation (SDG) involves training a machine learning model to masterthe statistical patterns and properties of a real dataset.
  • The companyisa pioneer in the development of unique technologies for generating privacy-protective synthetic data that maintain the statistical properties of real-world data (RWD).

Lucence Presents Data at 2022 World Conference on Lung Cancer (WCLC) Supporting Utility of Amplicon-Based Liquid Biopsy From Detection Through Treatment

Retrieved on: 
Wednesday, July 13, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Lung, NGS, BRCA, Conference, Gene, EGFR, Abstract (summary), Mutation, Medicine, NSCLC, Biomarker, CLIA, Patient, Neoplasm, Large-cell lung carcinoma, PLOS ONE, Plasma, Somatic mutation, CtRNA, Lung cancer, PLOS, TCR, Nucleic acid thermodynamics, VAF, Liquid biopsy, Medical imaging

Lucence will present new data at the upcoming IASLC 2022 World Conference on Lung Cancer on August 6-9, 2022, highlighting novel applications of its ultrasensitive amplicon-based next generation sequencing technology in the detection and treatment of lung cancer.

Key Points: 
  • Lucence will present new data at the upcoming IASLC 2022 World Conference on Lung Cancer on August 6-9, 2022, highlighting novel applications of its ultrasensitive amplicon-based next generation sequencing technology in the detection and treatment of lung cancer.
  • Liquid biopsy will continue to transform the way we diagnose, treat, and understand lung cancer, said Min-Han Tan, Founding CEO and Medical Director at Lucence.
  • Abstracts to be presented in poster presentations at the conference build on Lucences continued innovation in liquid biopsy in the detection, treatment, and monitoring of lung cancer.
  • 14.3% additional lung cancer cases were detected compared to ctDNA detection alone, demonstrating the utility of a multi-signal cfDNA approach for sensitive detection of lung cancer.

New Research Reveals Top Three Barriers Keeping Children from Cataract Treatment in India

Retrieved on: 
Tuesday, January 11, 2022
Orbis, Ophthalmology, Orbis International, Research, Cataract, Candid (organization), Nursing, Pediatric ophthalmology, Intention, Parent, Community, Travel, Knowledge, Health, Moran Eye Center, Motivation, Organic, Severe cognitive impairment, Spirituality, Goal, Government, MD-10, Caregiver, Diagnosis, PLOS, Communication, PLOS ONE, Child, University, Hospital, Internet, Medical device, Health insurance, Medicine, Toy, Residential care

The research outlines the findings of in-depth interviews conducted with parents and caregivers across India that were used to determine the top barriers to accessing sight-saving cataract treatment for their children.

Key Points: 
  • The research outlines the findings of in-depth interviews conducted with parents and caregivers across India that were used to determine the top barriers to accessing sight-saving cataract treatment for their children.
  • An understanding of these barriers and enablers can be used to improve parents' timely uptake of services for their children.
  • For children born with the condition, the average age of treatment is 4 years old, while children who develop cataract(s) later are, on average, 8 years of age before receiving surgery.
  • The comprehensive findings from this research have enabled Orbis to understand parents' perceived barriers and enablers to accessing childhood cataract services, which will be targeted in all future interventions in India to improve timely uptake of cataract services by children.

PanTheryx Unveils New Bovine Colostrum Product, ColostrumOne™ Extra Strength, at SupplySide West 2021

Retrieved on: 
Tuesday, October 26, 2021
Retail, Health, Fitness & Nutrition, General Health, Food, Beverage, Biotechnology, Veterinary, PLOS ONE, Digestion, Technology, Immunoglobulin G, Tablet, Stomach, Innovation, PLOS, Capsule, Colostrum, GI, Inflammation, Colitis, Health, Milk, Vaccine

The study demonstrated ColostrumOne Extra Strengths ability to protect against intestinal damage and inflammation.

Key Points: 
  • The study demonstrated ColostrumOne Extra Strengths ability to protect against intestinal damage and inflammation.
  • We developed our new ColostrumOne Extra Strength with a unique matrix technology to protect the bioactive components of colostrum and to enhance bioavailability.
  • Attendees at this years SupplySide West event can visit the PanTheryx APS La Belle booth #3226 to learn more about ColostrumOne Extra Strength and the companys line of colostrum product offerings.
  • As the worlds largest producer of colostrum, PanTheryx provides its proprietary ColostrumOne and La Belle Colostrum ingredients to its partners serving the global human and animal health markets.

Women with IDD Fall Through Healthcare Cracks, Have Poorer Pregnancy Outcomes

Retrieved on: 
Monday, August 23, 2021
Pregnancy, Population, University, Quality of life, Disability in Canada, Intellect, PLOS ONE, Physician, Family, Pre-eclampsia, Risk, Research, Prenatal care, Health, Intellectual, McGowan, Child, PLOS, IDD, College of Family Physicians of Canada, Goal, History, Education, Cincinnati Center City Development Corporation, Verbal abuse, Birth control, Medicine

Dr. Craig Escud, President of IntellectAbility , says, "The fact is, women with IDD can and do become pregnant.

Key Points: 
  • Dr. Craig Escud, President of IntellectAbility , says, "The fact is, women with IDD can and do become pregnant.
  • (2) Compared to females without IDD, women with IDD are also less likely to have access to prenatal care in the first trimester and to breastfeed.
  • (3)
    The prenatal experience of women with IDD often differs greatly compared to those without IDD.
  • And when it comes to pregnancy, the same level of prenatal care should be accessible and available to anyone, including women with IDD.